Andrei A. Leonov

Goettingen, NI, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

The PET tracer [11C]MODAG-005 targets alpha-synuclein aggregates in the brain.

The PET tracer [11C]MODAG-005 targets alpha-synuclein aggregates in the brain.

Journal: Science translational medicine

Published: May 27, 2026

Anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formation.

Anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formation.

Journal: Nature communications

Published: May 28, 2025

Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease.

Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease.

Journal: EMBO molecular medicine

Published: March 05, 2025

Seeing Double: The Persistent Dimer-of-Dimers Structure of Drug Resistant Influenza A M2.

Seeing Double: The Persistent Dimer-of-Dimers Structure of Drug Resistant Influenza A M2.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: August 25, 2024

Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins.

Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins.

Journal: Melanoma research

Published: July 01, 2024

Anle138b interaction in α-synuclein aggregates by dynamic nuclear polarization NMR.

Anle138b interaction in α-synuclein aggregates by dynamic nuclear polarization NMR.

Journal: Methods (San Diego, Calif.)

Published: November 30, 2022

Real-time tracking of drug binding to influenza A M2 reveals a high energy barrier.

Real-time tracking of drug binding to influenza A M2 reveals a high energy barrier.

Journal: Journal of structural biology: X

Published: August 17, 2022

The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils.

The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils.

Journal: Nature communications

Published: May 05, 2022

Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial.

Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial.

Journal: EBioMedicine

Published: September 17, 2021

[11C]MODAG-001-towards a PET tracer targeting α-synuclein aggregates.

[11C]MODAG-001-towards a PET tracer targeting α-synuclein aggregates.

Journal: European journal of nuclear medicine and molecular imaging

Published: July 09, 2020

Lanthanide Tagging of Oligonucleotides to Nucleobase for Paramagnetic NMR.

Lanthanide Tagging of Oligonucleotides to Nucleobase for Paramagnetic NMR.

Journal: Chembiochem : a European journal of chemical biology

Published: June 29, 2020

Membrane-embedded TSPO: an NMR view.

Membrane-embedded TSPO: an NMR view.

Journal: European biophysics journal : EBJ

Published: May 22, 2020

Showing 1-12 of 38

Last Updated: 09/26/2026